These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15897317)

  • 1. Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment.
    Lim AY; Ostor AJ; Love S; Crisp AJ
    Ann Rheum Dis; 2005 Jun; 64(6):965-6. PubMed ID: 15897317
    [No Abstract]   [Full Text] [Related]  

  • 2. Multimodal therapy for vertebral involvement of systemic mastocytosis.
    Krüger A; Hamann C; Brendel C; Ramaswamy A; Schnabel M; Neubauer A; Hofbauer LC
    Spine (Phila Pa 1976); 2009 Aug; 34(17):E626-8. PubMed ID: 19644322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic mast cell disease: a rare cause of osteoporosis.
    Cacace E; Salis G; Ruggiero V; Perpignano G
    Clin Exp Rheumatol; 2006; 24(2):210. PubMed ID: 16762162
    [No Abstract]   [Full Text] [Related]  

  • 4. [Severe therapy refractive osteoporosis : A rare differential diagnosis].
    Gehlen M; Lazarescu AD; Hinz C; Schmidt N; Pfeifer M; Werner M; Weidemann HF; Schwarz-Eywill M; Maier A
    Z Rheumatol; 2016 Sep; 75(7):729-35. PubMed ID: 27193336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Systemic mastocytosis--rare cause of pathologic vertebral fracture].
    Stamm AC; Burbelko M; Rominger M
    Rofo; 2008 Jan; 180(1):57-9. PubMed ID: 17968773
    [No Abstract]   [Full Text] [Related]  

  • 6. [Systemic mastocytosis as a cause of osteoporosis].
    Kemink SA; Smals AG; Kloppenborg PW
    Ned Tijdschr Geneeskd; 1996 Jun; 140(24):1277-9. PubMed ID: 8700283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic mastocytosis: a rare cause of osteoporosis.
    Garla VV; Chaudhary KUQ; Yaqub A
    Pan Afr Med J; 2019; 32():169. PubMed ID: 31303938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: pathologic long bone fracture in a patient with systemic mastocytosis.
    King JJ; Crawford EA; Iwenofu OH; Fox EJ
    Clin Orthop Relat Res; 2007 Jun; 459():263-9. PubMed ID: 17327804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of urticaria pigmentosa to cladribine in a patient with systemic mastocytosis.
    Bennett M; Chubar Y
    Br J Haematol; 2013 Feb; 160(4):420. PubMed ID: 23205635
    [No Abstract]   [Full Text] [Related]  

  • 11. [Osteoporosis as a first manifestation of systemic mastocytosis. Study of 6 cases].
    Sallés M; Holgado S; Navarro JT; Ribera JM; Riera E; Millà F; Tena X
    Med Clin (Barc); 2007 Feb; 128(6):216-8. PubMed ID: 17335726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
    Cruse LM; Valeriano J; Vasey FB; Carter JD
    J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic mastocytosis in association with chronic lymphocytic leukemia: a rare diagnosis.
    Ault P; Lynn A; Tam CS; Medeiros LJ; Keating MJ
    Leuk Res; 2007 Dec; 31(12):1755-8. PubMed ID: 17521719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.
    González de Olano D; Alvarez-Twose I; Esteban-López MI; Sánchez-Muñoz L; de Durana MD; Vega A; García-Montero A; González-Mancebo E; Belver T; Herrero-Gil MD; Fernández-Rivas M; Orfao A; de la Hoz B; Castells MC; Escribano L
    J Allergy Clin Immunol; 2008 Feb; 121(2):519-26. PubMed ID: 18177694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart transplantation in a patient with systemic mastocytosis.
    Moro JA; Almenar L; Jarque I; Martinez-Dolz L; Hernández MD; Crespo M; Salvador A
    J Heart Lung Transplant; 2008 Jun; 27(6):689-91. PubMed ID: 18503972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy.
    Yao S; McCarthy PL; Dunford LM; Roy DM; Brown K; Paplham P; Syta M; Lamonica D; Smiley S; Battiwalla M; Padmanabhan S; Hahn T
    Bone Marrow Transplant; 2008 Feb; 41(4):393-8. PubMed ID: 17994116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic mastocytosis associated with severe osteoporosis in a male patient.
    Gil-Diaz A; Delgado-Martinez JR; Suarez-Ortega S; Rivero-Vera JC; Lorenzo-Rivero JA; Betancor-Leon P
    Intern Med J; 2013 Apr; 43(4):461-2. PubMed ID: 23551312
    [No Abstract]   [Full Text] [Related]  

  • 19. Persistence with bisphosphonate therapy in older people.
    Melo M; Qiu F; Sykora K; Juurlink D; Laupacis A; Mamdani M
    J Am Geriatr Soc; 2006 Jun; 54(6):1015-6. PubMed ID: 16776810
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic Mastocytosis: documented pathologic response to imatinib.
    Gollard RP; Ruemmler-Fish C; Garcia D
    Eur J Haematol; 2007 Oct; 79(4):367-8. PubMed ID: 17655701
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.